Literature DB >> 8195910

Outcomes of treatment of socially rehabilitated methadone maintenance patients in physicians' offices (medical maintenance): follow-up at three and a half to nine and a fourth years.

D M Novick1, H Joseph, E A Salsitz, M F Kalin, J B Keefe, E L Miller, B L Richman.   

Abstract

OBJECTIVE: To determine whether selected socially rehabilitated former heroin addicts maintained on methadone can continue successful rehabilitation while maintained on methadone by primary care physicians rather than licensed clinics. This procedure has been termed "medical maintenance."
DESIGN: Cohort study with 42-111 months of follow-up.
SETTING: Offices of hospital staff physicians (internists or family practitioners). PATIENTS: The 100 patients met extensive entry criteria, including five or more years in conventional methadone maintenance treatment; stable employment or other productive activity; verifiable financial support; and no criminal involvement, use of illegal drugs, or excessive alcohol use within three or more years.
MEASUREMENTS AND MAIN RESULTS: Outcome measures used were retention in treatment, discharge for one of several reasons, lost medication incidents, and substance abuse. At one, two, and three years of treatment, 98, 95, and 85 patients, respectively, remained in medical maintenance. Cumulative proportional survival in treatment was 0.735 +/- 0.048 at five years and 0.562 +/- 0.084 at nine years. After 42-111 months, 72 patients remained in good standing; 15 patients had unfavorable discharges (11 for cocaine use, three for misuse of medication, and one for administrative violations); seven voluntarily withdrew from methadone in good standing (after receiving it for 9.1-24.4 years); four died; one transferred to a chronic care facility; and one voluntarily left the program.
CONCLUSIONS: Carefully selected methadone maintenance patients in medical maintenance have a high retention rate and a low incidence of substance abuse and lost medication. Voluntary withdrawal from methadone maintenance after one or two decades is possible. The authors believe that medical maintenance should be made available to appropriate patients in other localities.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8195910     DOI: 10.1007/bf02600025

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN: 0884-8734            Impact factor:   5.128


  15 in total

1.  Hazards of process regulations. The example of methadone maintenance.

Authors:  V P Dole
Journal:  JAMA       Date:  1992 Apr 22-29       Impact factor: 56.272

Review 2.  Using methadone effectively: achieving goals by application of laboratory, clinical, and evaluation research and by development of innovative programs.

Authors:  M J Kreek
Journal:  NIDA Res Monogr       Date:  1991

3.  Consequences and costs of shutting off methadone.

Authors:  M D Anglin; G R Speckart; M W Booth; T M Ryan
Journal:  Addict Behav       Date:  1989       Impact factor: 3.913

4.  Narcotic blockade.

Authors:  V P Dole; M E Nyswander; M J Kreek
Journal:  Arch Intern Med       Date:  1966-10

5.  Long-term outcome of patients treated with methadone maintenance.

Authors:  V P Dole; H Joseph
Journal:  Ann N Y Acad Sci       Date:  1978       Impact factor: 5.691

6.  Intravenous drug use, methadone, and AIDS: ask not for whom the bell tolls.

Authors:  B Stimmel
Journal:  J Addict Dis       Date:  1993

7.  Sounding board. The crisis in methadone maintenance.

Authors:  N E Zinberg
Journal:  N Engl J Med       Date:  1977-04-28       Impact factor: 91.245

Review 8.  Implications of methadone maintenance for theories of narcotic addiction.

Authors:  V P Dole
Journal:  JAMA       Date:  1988-11-25       Impact factor: 56.272

9.  "Living with the dirty secret": problems of disclosure for methadone maintenance clients.

Authors:  S Murphy; J Irwin
Journal:  J Psychoactive Drugs       Date:  1992 Jul-Sep
View more
  15 in total

Review 1.  Office-based maintenance treatment of opioid dependence: how does it compare with traditional approaches?

Authors:  Erik W Gunderson; David A Fiellin
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

2.  Density of low-barrier opioid agonist clinics and risk of non-fatal overdose during a community-wide overdose crisis: A spatial analysis.

Authors:  Ofer Amram; Eugenia Socías; Ekaterina Nosova; Thomas Kerr; Evan Wood; Kora DeBeck; Kanna Hayashi; Nadia Fairbairn; Julio Montaner; M J Milloy
Journal:  Spat Spatiotemporal Epidemiol       Date:  2019-07-04

3.  Addiction treatment: promoting a medical approach to substance use.

Authors:  G L Stein; A R Fleischman
Journal:  J Urban Health       Date:  1998-09       Impact factor: 3.671

4.  Methadone treatment. Clinical judgment is important.

Authors:  C Brewer; C Neill
Journal:  BMJ       Date:  1996-12-07

Review 5.  Mainstreaming methadone maintenance treatment: the role of the family physician.

Authors:  M Latowsky; E Kallen
Journal:  CMAJ       Date:  1997-08-15       Impact factor: 8.262

6.  Heroin Use, HIV-Risk, and Criminal Behavior in Baltimore: Findings from Clinical Research.

Authors:  Robert P Schwartz; Sharon M Kelly; Jan Gryczynski; Shannon Gwin Mitchell; Kevin E O'Grady; Jerome H Jaffe
Journal:  J Addict Dis       Date:  2015

7.  The Physician Clinical Support System-Buprenorphine (PCSS-B): a novel project to expand/improve buprenorphine treatment.

Authors:  James E Egan; Paul Casadonte; Tracy Gartenmann; Judith Martin; Elinore F McCance-Katz; Julie Netherland; John A Renner; Linda Weiss; Andrew J Saxon; David A Fiellin
Journal:  J Gen Intern Med       Date:  2010-05-11       Impact factor: 5.128

Review 8.  Treatment of heroin (diamorphine) addiction: current approaches and future prospects.

Authors:  Gerardo Gonzalez; Alison Oliveto; Thomas R Kosten
Journal:  Drugs       Date:  2002       Impact factor: 9.546

9.  The impact of low-threshold methadone maintenance treatment on mortality in a Canadian setting.

Authors:  Seonaid Nolan; Kanna Hayashi; M-J Milloy; Thomas Kerr; Huiru Dong; Viviane Dias Lima; Leslie Lappalainen; Julio Montaner; Evan Wood
Journal:  Drug Alcohol Depend       Date:  2015-09-28       Impact factor: 4.492

10.  Factors affecting willingness to provide buprenorphine treatment.

Authors:  Julie Netherland; Michael Botsko; James E Egan; Andrew J Saxon; Chinazo O Cunningham; Ruth Finkelstein; Mark N Gourevitch; John A Renner; Nancy Sohler; Lynn E Sullivan; Linda Weiss; David A Fiellin
Journal:  J Subst Abuse Treat       Date:  2008-08-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.